← Bin Chen Lab

Center for AI-Enabled Drug Discovery (AID)

Democratizing AI-based drug discovery in academia

What We Do

The mission of AID in the College of Human Medicine at Michigan State University (MSU) is to bring together AI, big data, and the local drug discovery community; to train the next generation of scientists with specialized expertise; and ultimately to grow into a sustainable research and education program.

To achieve research excellence, AID leverages emerging big data (e.g., single-cell and spatial transcriptomics, electronic health records), state-of-the-art AI methods (e.g., graph neural networks, transfer learning, deep reinforcement learning), and advanced preclinical models (e.g., ex vivo tissue slice cultures, organoids). AID takes a novel, patient-centric approach: drugs are proposed based on RNA features derived from patients and then validated in models derived from patient tissues.

AID supports both the repurposing of existing drugs for new indications, which can speed up discovery and approval, and the discovery of novel compounds, which takes longer but offers new therapeutic approaches and intellectual property. A key strength of AID is its unique transcriptomics-based drug discovery platform, developed by our team members.

RNA-based drug discovery platform

How We Make Discoveries

AID discovery workflow, from patient omics profiling through AI screening, optimization, and in vivo testing

Idiopathic pulmonary fibrosis (IPF) is shown as an example.

Drug Discovery Pipeline

Indication Lead investigators Status Goal Funding
HCC Samuel So, Mei-Sze Chua (Stanford) Graduated Novel NIH R01 GM134307; NIH R01 GM145700 (scored 7%)
DIPG Rintaro Hashizume (UAB) PK / In vivo Novel NIH R01 GM145700
IPF Xiaopeng Li (MSU), Reda Girgis (Corewell) Lead optimization Repurposing / Novel SPG; NIH R61 HL177451
Prostate cancer bone metastasis Xiaohong Li (University of Toledo) In vivo Novel DoD HT94252410133; NIH R01 CA286189 (scored 5%)
Mesenchymal stem cell dedifferentiation Ling Huang (HFH) In vitro Repurposing SPG
Endometriosis Asgi Fazleabas (MSU) In vitro Repurposing NIH R01 pending (scored 4%)
AML Sachi Horibata (MSU) In vitro Repurposing Foundation; startup funds
Alzheimer's disease Dave Morgan (MSU) In silico Repurposing NIH R01 submitted
Pediatric MODS Surender Rajasekaran (Corewell) Signature discovery Repurposing NIH R01 GM134307; NIH K99 HD111575
Cardiogenic shock Brian Trethowan, Renzo Loyaga Rendon (Corewell) Signature discovery Repurposing Corewell-MSU Alliance
Uterine fibroids Emmanuel Paul (MSU) Signature discovery Novel NIH K99 HD112539
YAP inhibitor combination Xin Chen (University of Hawaii), Xu Wu (Harvard) In vitro Repurposing NIH R01 submitted

Status stages: Signature discovery → In silico → In vitro → Lead optimization → PK → In vivo → Graduated

Core Team

Bin Chen

Bin Chen, PhD

PI · AI Drug Discovery

Previously at Stanford, UCSF, Novartis, Pfizer, and Merck

Edmund Ellsworth

Edmund Ellsworth, PhD

Co-PI · Medicinal Chemistry

Co-Director, MSU Drug Discovery Program

Rick Neubig

Rick Neubig, MD, PhD

Co-PI · Drug Discovery

Director Emeritus, MSU Drug Discovery Program

Jiayu Zhou

Jiayu Zhou, PhD

Co-PI · AI Research and Education

Computer Science and Engineering

Yuehua Cui

Yuehua Cui, PhD

Co-PI · AI Research and Education

Statistics and Probability

Dmitry Leshchiner

Dmitry Leshchiner, MD

Lead · AI Drug Discovery

Postdoctoral scholar, Chen Lab

Publications

Data, Models, and Tools

Discovery